Melissa H. Boyd

Cooley advised digital health automation company Olive on its $400 million funding round, which brings its valuation to $4 billion. Lawyers Peter Werner and Melissa Boyd led the Cooley team advising Olive.

Cooley advised oncology-focused biopharmaceutical company Nuvation Bio on its agreement to combine with Panacea, a special purpose acquisition company or SPAC, sponsored by EcoR1 Capital. Upon closing, which is expected in Q1 2021, Panacea will be renamed Nuvation Bio, and its common stock will be listed on the New York Stock Exchange under the new symbol “NUVB.” Cooley partners Kenneth Guernsey, Rama Padmanabhan and John McKenna led the team advising Nuvation on the agreement.

Cooley advised healthcare software company Olive on its $225.5 million financing round led by Tiger Global, as well as its acquisition of Verata Health to accelerate artificial intelligence technology for healthcare providers and payers. Partner Peter Werner led the Cooley teams advising Olive on the transactions.

Cooley advised Levi Strauss on its $623 million initial public offering of 36,666,667 shares of common stock. Eric Jensen, Jodie Bourdet and Siana Lowrey led the Cooley team advising Levi Strauss.

Goldman Sachs and J.P. Morgan served as joint lead book-running managers for the offering. BofA Merrill Lynch, Morgan Stanley and Evercore Group served as book-running managers and BNP Paribas, Citigroup, Guggenheim Securities, HSBC, Drexel Hamilton, Telsey Advisory and The Williams Capital Group served as co-managers.

Levi Strauss is an iconic blue jeans and apparel company with products sold in more than 110 countries worldwide. The company’s shares now trade on the NYSE under the symbol “LEVI.”

Cooley advised Principia Biopharma on its $122.2 million initial public offering of 7,187,500 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares. Lawyers David Peinsipp, Drew Williamson, Barbara Kosacz and Amanda Busch led the Cooley team advising the company.

Bank of America Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as joint book-running managers for the offering. Robert W. Baird acted as lead manager.

Principia Biopharma, which now trades on the Nasdaq Global Select Market as “PRNB,” is a biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.